Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2015', provides an overview of the Proliferative Vitreoretinopathy (PVR)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Proliferative Vitreoretinopathy (PVR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Vitreoretinopathy (PVR) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Proliferative Vitreoretinopathy (PVR) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Proliferative Vitreoretinopathy (PVR) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Proliferative Vitreoretinopathy (PVR) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Proliferative Vitreoretinopathy (PVR) Overview 6 Therapeutics Development 7 Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview 7 Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis 8 Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies 9 Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes 10 Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance 11 Early Stage Products 11 Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies 12 Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes 13 Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development 14 Promedior, Inc. 14 RXi Pharmaceuticals Corporation 15 Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Drug Profiles 24 Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 LD-224 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Oligonucleotide 2 for Age Related Macular Degeneration and Proliferative Vitreoretinopathy - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Oligonucleotide for Age Related Macular Degeneration and Proliferative Vitreoretinopathy - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PRM-167 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Proliferative Vitreoretinopathy (PVR) - Recent Pipeline Updates 32 Proliferative Vitreoretinopathy (PVR) - Dormant Projects 33 Proliferative Vitreoretinopathy (PVR) - Product Development Milestones 34 Featured News & Press Releases 34 Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences 34 May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform 35 May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering Technology Platform 36 May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 36 May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2015 7 Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2015 8 Number of Products under Development by Companies, H2 2015 9 Number of Products under Investigation by Universities/Institutes, H2 2015 10 Comparative Analysis by Early Stage Development, H2 2015 11 Products under Development by Companies, H2 2015 12 Products under Investigation by Universities/Institutes, H2 2015 13 Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior, Inc., H2 2015 14 Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 15 Assessment by Monotherapy Products, H2 2015 16 Number of Products by Stage and Target, H2 2015 18 Number of Products by Stage and Mechanism of Action, H2 2015 20 Number of Products by Stage and Route of Administration, H2 2015 21 Number of Products by Stage and Molecule Type, H2 2015 23 Proliferative Vitreoretinopathy (PVR) Therapeutics - Recent Pipeline Updates, H2 2015 32 Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H2 2015 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
